Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 3/20 | 0.43 |
| ▸ | ACE | P12821 | 3/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22802834 | 0.92 | MME (0.53) | MMEACEACE2CPA1CTSS | |
| SCHEMBL26881064 | 0.92 | MME (0.53) | MMEACEACE2CPA1CTSS | |
| SCHEMBL22508553 | 0.86 | FOLH1 (0.47) | MAPTMMEACEACE2CPA1 | |
| SCHEMBL25070896 | 0.84 | TSHR (0.49) | NPC1RAB9AALDH1A1HPGDMME | |
| SCHEMBL24024021 | 0.84 | TSHR (0.49) | NPC1RAB9AALDH1A1HPGDMME | |
| SCHEMBL24168623 | 0.83 | TAAR1 (0.47) | NPC1RAB9AMAPTALDH1A1NPSR1 | |
| SCHEMBL16724755 | 0.83 | TAAR1 (0.47) | NPC1RAB9AMAPTALDH1A1NPSR1 | |
| SCHEMBL15592756 | 0.83 | MME (0.58) | NPC1RAB9ANPSR1MMEACE | |
| SCHEMBL2781126 | 0.83 | MME (0.58) | NPC1RAB9ANPSR1MMEACE | |
| SCHEMBL123574 | 0.83 | MME (0.58) | NPC1RAB9ANPSR1MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053449-A1 | DC-SIGN ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230053449-A1 | DC-SIGN ANTIBODY DRUG CONJUGATES | DCUN1D4, CD14, DCUN1D3 | NPC1 342/4885RAB9A 429/4885MAPT 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.